American Journal of Cardiology
Volume 106, Issue 5 , Pages 650-658 , 1 September 2010

Usefulness of Biomarker Strategy to Improve GRACE Score's Prediction Performance in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome and Low Event Rates

  • Farzin Beygui, MD, PhD

      Affiliations

    • Department of Cardiology and INSERM, U937, Pitié-Salpêtrière University Hospital–APHP, Paris, France
    • ,
  • Johanne Silvain, MD

      Affiliations

    • Department of Cardiology and INSERM, U937, Pitié-Salpêtrière University Hospital–APHP, Paris, France
    • ,
  • Ana Pena, PhD

      Affiliations

    • Department of Cardiology and INSERM, U937, Pitié-Salpêtrière University Hospital–APHP, Paris, France
    • ,
  • Anne Bellemain-Appaix, MD

      Affiliations

    • Department of Cardiology and INSERM, U937, Pitié-Salpêtrière University Hospital–APHP, Paris, France
    • ,
  • Jean-Philippe Collet, MD, PhD

      Affiliations

    • Department of Cardiology and INSERM, U937, Pitié-Salpêtrière University Hospital–APHP, Paris, France
    • ,
  • Helmut Drexler, MD, PhD

      Affiliations

    • Hochschule Hannover, Hannover, Germany
    • ,
  • Deepak Bhatt, MD

      Affiliations

    • Cleveland Clinic, Cleveland, Ohio
    • ,
  • Eric Vicaut, MD, PhD

      Affiliations

    • Clinical Research Unit, Lariboisière-Fernand Widal University Hospital–APHP, Paris, France
    • ,
  • Gilles Montalescot, MD, PhD

      Affiliations

    • Department of Cardiology and INSERM, U937, Pitié-Salpêtrière University Hospital–APHP, Paris, France
    • Corresponding Author InformationCorresponding author: Tel: (33) 1-4216-3006; fax: (33) 1-4216-2931

Received 9 February 2010 ,Revised 15 April 2010 ,Accepted 15 April 2010.

Reference 

  1. Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333:1091
  2. Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004;291:2727–2733
  3. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation. 1999;99:855–860
  4. Hartford M, Wiklund O, Mattsson Hulten L, Persson A, Karlsson T, Herlitz J, et al. C-reactive protein, interleukin-6, secretory phospholipase A2 group IIA and intercellular adhesion molecule-1 in the prediction of late outcome events after acute coronary syndromes. J Intern Med. 2007;262:526–536
  5. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med. 2000;343:1139–1147
  6. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 1994;331:417–424
  7. Mueller C, Buettner HJ, Hodgson JM, Marsch S, Perruchoud AP, Roskamm H, et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation. 2002;105:1412–1415
  8. Rallidis LS, Zolindaki MG, Manioudaki HS, Laoutaris NP, Velissaridou AH, Papasteriadis EG. Prognostic value of C-reactive protein, fibrinogen, interleukin-6, and macrophage colony stimulating factor in severe unstable angina. Clin Cardiol. 2002;25:505–510
  9. Steg PG, Ravaud P, Tedgui A, Puel J, Moyse D, Curaudeau E, et al. Predischarge C-reactive protein and 1-year outcome after acute coronary syndromes. Am J Med. 2006;119:684–692
  10. Biasucci LM, Liuzzo G, Fantuzzi G, Caligiuri G, Rebuzzi AG, Ginnetti F, et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation. 1999;99:2079–2084
  11. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA. 2001;286:2107–2113
  12. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349:1595–1604
  13. Sinha MK, Gaze DC, Tippins JR, Collinson PO, Kaski JC. Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation. 2003;107:2403–2405
  14. Mallat Z, Steg PG, Benessiano J, Tanguy ML, Fox KA, Collet JP, et al. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol. 2005;46:1249–1257
  15. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003;107:1579–1585
  16. Kelly D, Khan SQ, Thompson M, Cockerill G, Ng LL, Samani N, et al. Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur Heart J. 2008;29:2116–2124
  17. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003;348:1104–1111
  18. Mega JL, Morrow DA, De Lemos JA, Sabatine MS, Murphy SA, Rifai N, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol. 2004;44:335–339
  19. Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation. 2003;107:2786–2792
  20. Beygui F, Collet JP, Benoliel JJ, Vignolles N, Dumaine R, Barthelemy O, et al. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation. 2006;114:2604–2610
  21. Beygui F, Montalescot G, Vicaut E, Rouanet S, Van Belle E, Baulac C, et al. Aldosterone and long-term outcome after myocardial infarction: a substudy of the French nationwide Observatoire sur la Prise en charge hospitaliere, l'Evolution a un an et les caRacteristiques de patients presentant un infArctus du myocarde avec ou sans onde Q (OPERA) study. Am Heart J. 2009;157:680–687
  22. Palmer BR, Pilbrow AP, Frampton CM, Yandle TG, Skelton L, Nicholls MG, et al. Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. Eur Heart J. 2008;29:2489–2496
  23. Montalescot G, Drexler H, Gallo R, Pearson T, Thoenes M, Bhatt DL. Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHIPELAGO study. Eur Heart J. 2009;30:2733–2741
  24. Steg PG, Joubin L, McCord J, Abraham WT, Hollander JE, Omland T, et al. B-type natriuretic peptide and echocardiographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea. Chest. 2005;128:21–29
  25. Ang DS, Wei L, Kao MP, Lang CC, Struthers AD. A comparison between B-type natriuretic peptide, Global Registry of ACUTE CORONARY EVENTS (GRACE) score and their combination in ACS risk stratification. Heart. 2009;95:1836–1842
  26. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321
  27. Thompson MM, Squire IB. Matrix metalloproteinase-9 expression after myocardial infarction: physiological or pathological?. Cardiovasc Res. 2002;54:495–498
  28. Squire IB, Evans J, Ng LL, Loftus IM, Thompson MM. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail. 2004;10:328–333

 The Irbesartan in Patients With Acute Coronary Syndrome Without ST Segment Elevation (ARCHIPELAGO) trial was entirely funded by Sanofi-Aventis, Paris, France.

 Dr. Beygui has received lecture fees from Sanofi-Aventis, Paris, France, Pfizer, New York, New York, and Astellas, Tokyo, Japan. Dr. Silvain has received research grants from Daiichi-Sankyo, Tokyo, Japan, Eli Lilly, Indianapolis, Indiana, and Sanofi-Aventis, Paris, France. Dr. Collet has received research grants from Bristol-Myers Squibb, Markham, Canada, Sanofi-Aventis, Paris, France, Eli Lilly, Indianapolis, Indiana, Guerbet Medical, Villepinte, France, Medtronic, Minneapolis, Minnesota, Boston Scientific, Natick, Michigan, Cordis, Bridgewater, New Jersey, Stago, Asnières sur seine, France, and Centocor, Ridgeview, Pennsylvania; consulting fees from Sanofi-Aventis, Paris, France, Eli Lilly, Indianapolis, Indiana, and Bristol-Myers Squibb, Markham, Canada; and lecture fees from Bristol-Myers Squibb, Markham, Canada, Sanofi-Aventis, Paris, France, and Eli Lilly, Indianapolis, Indiana. Dr. Montalescot has received research grants from BMS, Sanofi-Aventis, Paris, France, Eli Lilly, Indianapolis, Indiana, Guerbet Medical, Villepinte, France, Medtronic, Minneapolis, Minnesota, Boston Scientific, Natick, Michigan, Cordis, Bridgewater, New Jersey, Stago, Asnières sur seine, France, Centocor, Ridgeview, Pennsylvania, ITC Edison, Novi, Michigan, and Pfizer, New York, New York, and consulting fees from Sanofi-Aventis, Paris, France, Eli Lilly, Indianapolis, Indiana, BMS, The Medicines Company, Parcipanny, New Jersey, Schering-Plough, Kenilworth, New Jersey, Portola, S San Francisco, California, Novartis, Basle, Switzerland, Menarini, Florence, Italy, Eisai, Woodcliff lake, New Jersey, Daiichi, Bayer, Leverkusen, Germany, and Boehringer Ingelheim, Ingelheim am Rhein, Germany; and lecture fees from Sanofi-Aventis, Paris, France, Eli Lilly, Indianapolis, Indiana, BMS, Merck Sharpe and Dohme, Whitehouse station, New Jersey, Cordis, Bridgewater, New Jersey, GlaxoSmithKline, London, United Kingdom, Schering-Plough, Kenilworth, New Jersey, Accumetrics, San Diego, California, AstraZeneca, Wilmington, Delaware, Daiichi, and Menarini, Florence, Italy. Dr. Vicaut has received consulting fees from Pfizer, New York, New York.

PII: S0002-9149(10)00955-0

doi: 10.1016/j.amjcard.2010.04.019

American Journal of Cardiology
Volume 106, Issue 5 , Pages 650-658 , 1 September 2010

Article Tools

* Image Usage & Resolution